Literature DB >> 28593486

Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease.

Homare Shimohata1, Hiroshi Maruyama2, Yasunori Miyamoto2, Mamiko Takayasu2, Kouichi Hirayama2, Masaki Kobayashi2.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by a lack of α-galactosidase A activity, which leads to the accumulation of globotriaosylceramide in various organs. A complete lack of α-galactosidase A activity in a hemizygous male is the classical phenotype, and some hemizygous males show primarily cardiac and/or renal symptoms that appear in adulthood; this is called the variant type or the late-onset type. The kidney and heart are the major target organs, with damage to these organs related to mortality. Thus, in Fabry patients, early detection and early treatment are critical to longevity. Here, we present a 55-year-old Japanese male patient who was diagnosed with late-onset Fabry nephropathy with cardiomyopathy but with no abnormal urinary findings except for urinary mulberry cells and mulberry bodies. In spite of the absence of abnormal urinary findings, the light microscopic and electron microscopic pathological findings showed extensive deposition of globotriaosylceramide to podocytes. In this paper, we propose that the presence of mulberry cells and mulberry bodies can be used for the earlier detection of Fabry nephropathy, especially the late-onset type.

Entities:  

Keywords:  Fabry nephropathy; Late-onset; Mulberry bodies; Mulberry cells

Year:  2017        PMID: 28593486      PMCID: PMC5694400          DOI: 10.1007/s13730-017-0262-5

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  16 in total

1.  Fabry's disease discovered with chance urinary mulberry cells: a case report.

Authors:  Takashi Nakamichi; Mariko Miyazaki; Keisuke Nakayama; Mitsuhiro Sato; Naoki Akiu; Toshinobu Sato; Hiroshi Sato; Sadayoshi Ito
Journal:  CEN Case Rep       Date:  2012-10-31

2.  Agalsidase benefits renal histology in young patients with Fabry disease.

Authors:  Camilla Tøndel; Leif Bostad; Kristin Kampevold Larsen; Asle Hirth; Bjørn Egil Vikse; Gunnar Houge; Einar Svarstad
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

3.  Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.

Authors:  Camilla Tøndel; Takahiro Kanai; Kristin Kampevold Larsen; Shuichi Ito; Juan Manuel Politei; David G Warnock; Einar Svarstad
Journal:  Nephron       Date:  2014-12-17       Impact factor: 2.847

4.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

5.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

6.  Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

Authors:  Alberto Ortiz; João P Oliveira; Christoph Wanner; Barry M Brenner; Stephen Waldek; David G Warnock
Journal:  Nat Clin Pract Nephrol       Date:  2008-04-22

7.  Fabry's disease: alpha-galactosidase deficiency.

Authors:  J A Kint
Journal:  Science       Date:  1970-02-27       Impact factor: 47.728

8.  Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

Authors:  C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

9.  Fabry Disease Diagnosed Based on the Detection of Urinary Mulberry Bodies.

Authors:  Tomoko Honda; Etsuko Komatsu; Satoshi Furuse; Naobumi Mise
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

10.  A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry Cells.

Authors:  Homare Shimohata; Yujiro Ogawa; Hiroshi Maruyama; Kouichi Hirayama; Masaki Kobayashi
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

View more
  5 in total

1.  Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.

Authors:  Homare Shimohata; Marina Yamashita; Kentaro Ohgi; Hiroshi Maruyama; Mamiko Takayasu; Kouichi Hirayama; Masaki Kobayashi
Journal:  CEN Case Rep       Date:  2020-03-18

2.  Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review.

Authors:  Hironobu Fujisawa; Yosuke Nakayama; Shoichiro Nakao; Ryo Yamamoto; Yuka Kurokawa; Nao Nakamura; Akiko Nagata; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba; Kei Fukami
Journal:  BMC Nephrol       Date:  2019-12-17       Impact factor: 2.388

3.  Fabry Disease with Pacemaker Implantation as the Initial Event.

Authors:  Yuji Kato; Ayako Ishikawa; Satoshi Aoki; Hiroyuki Sato; Yoshie Ojima; Saeko Kagaya; Tasuku Nagasawa
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

4.  Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy.

Authors:  Tsugumi Fukunaga; Shingo Nakayama; Takuo Hirose; Kishin Muramatsu; Akari Endo; Yuka Miyake; Go Anan; Ikuko Oba-Yabana; Atsuhiro Kanno; Hannah Nakamura; Junichi Tani; Kimitoshi Nakamura; Kazuhiro Sumitomo; Wako Yumura; Katsutoshi Furukawa; Takefumi Mori
Journal:  Case Rep Nephrol Dial       Date:  2021-11-29

5.  Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.

Authors:  Yumi Aoyama; Yusuke Ushio; Takashi Yokoyama; Sekiko Taneda; Shiho Makabe; Miki Nishida; Shun Manabe; Masayo Sato; Hiroshi Kataoka; Ken Tsuchiya; Kosaku Nitta; Toshio Mochizuki
Journal:  Intern Med       Date:  2020-04-01       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.